GAD-7 | Jotup

Mental Health Outcomes Demonstrate the Swift and Significant Impact of TimelyCare

Retrieved on:

수요일, 5월 1, 2024

FORT WORTH, Texas, May 1, 2024 /PRNewswire/ -- TimelyCare, higher education's most trusted virtual health and well-being provider, is swiftly and significantly improving the mental health of those who need support the most. This is highly important given mental health is the #1 reason students drop out of college.

Key Points:

This is highly important given mental health is the #1 reason students drop out of college.
TimelyCare began using Measurement-Based Care (MBC) last year, an evidence-based practice of tracking patient-reported progress in real-time to enhance treatment outcomes.
TimelyCare practitioners started collecting Patient Health Questionnaire (PHQ-9) and Generalized Anxiety Disorder Assessment (GAD-7) scores prior to Scheduled Counseling and Psychiatry visits.
"The TimelyCare MBC data underscore the correlation between improved mental health outcomes and student success," said Bob Booth, M.D., TimelyCare's Chief Care Officer.

QHSLab Announces Impressive 2023 Fiscal Year Results with Growing Revenues, Improved Gross Margins, and Substantial Reduction in Net Loss

Retrieved on:

목요일, 3월 28, 2024

Research, Financial management, Growth, Partnership, ISP, Patient, PALM, Mental health, GAD-7, Research and development, EHR, Marketing, Health, Nursing

Moreover, the Company significantly reduced its net operating loss, underscoring its enhanced operational efficiency and fiscal stewardship.

Key Points:

Moreover, the Company significantly reduced its net operating loss, underscoring its enhanced operational efficiency and fiscal stewardship.
Revenue Growth: QHSLab achieved revenues of $1,408,995 in 2023, a notable increase from $1,243,186 in 2022.
Gross Profit and Margin Improvement: The company generated a gross profit of $793,607 with a gross margin increase to 56.3% in 2023 from 49.8% in 2022.
Reduced Net Operating Loss: QHSLab markedly reduced its net operating loss to $(240,158) in 2023 from $(560,539) in 2022, highlighting the Company’s overall improvement in operating efficiency and financial management.

Clemson University Finds Hazel Health Teletherapy Program Drives Clinically Significant Outcomes in School Mental Health

Retrieved on:

화요일, 3월 19, 2024

BIPOC, GAD, Depression, Behaviorism, BCBA, Patient, SAN, School, Mental health, Research, GAD-7, PHQ, Anxiety, Hope, Doctor of Philosophy, Student, Adolescence, Anxiety disorder, Nursing

Hazel Health , the nation's largest school-based telehealth provider, today released the results of a third-party analysis demonstrating the clinical effectiveness of its proprietary teletherapy program for K-12 students, H.E.A.R.T™ (Hazel Early Assessment Response Treatment).

Key Points:

Hazel Health , the nation's largest school-based telehealth provider, today released the results of a third-party analysis demonstrating the clinical effectiveness of its proprietary teletherapy program for K-12 students, H.E.A.R.T™ (Hazel Early Assessment Response Treatment).
Each student-patient was scored for symptom severity pre vs. post-treatment (via the PHQ-9 for depression and the GAD-7 for anxiety).
The duration of the evidence-based treatment program was individualized to each participant, depending on their specific clinical needs at intake.
— William Edwards, PhD, BCBA, Director of the Center for Behavior Analysis at Clemson University Learning Institute.

MycoMeditations Surveys Show Lasting Benefits of Psilocybin Therapy for Major Depression and Anxiety Disorders

Retrieved on:

화요일, 2월 20, 2024

Psilocybin, GAD-7, Social anxiety, SAD, Mental health, Multimedia, PHQ-9, Treatment, Post-traumatic stress disorder, GAD, Anxiety, Generalized anxiety disorder, Social anxiety disorder, Major depressive disorder, Clinical trial, PTSD, MDD, Comment, Research

TREASURE BEACH, Jamaica, Feb. 20, 2024 /PRNewswire-PRWeb/ -- MycoMeditations, a pioneer in legal psilocybin-assisted therapy retreats, today announced the results of two years of longitudinal (long-term) client surveys exploring the impact of its psilocybin retreats on individuals suffering with Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Social Anxiety Disorder (SAD). The findings complement MycoMeditations' previously released surveys focused on Post-Traumatic Stress Disorder (PTSD).

Key Points:

The findings complement MycoMeditations' previously released surveys focused on Post-Traumatic Stress Disorder (PTSD).
MycoMeditations employed the PHQ-9, GAD-7, and SM-SAD-Adult questionnaires to measure self-reported symptom severity and long-term outcomes across MDD, GAD, and SAD, respectively.
Clinically significant improvements were maintained for one year following retreat for each Major Depressive Disorder, Generalized Anxiety, and Social Anxiety, suggesting possible long-term efficacy of psilocybin-assisted therapy.
The data suggests the viability of multiple psilocybin treatments in a short period of time when coupled with therapy, as MycoMeditations retreats are 7-nights with 3 psilocybin sessions on alternating days.

Greenspace Health & the Community Behavioral Health Association of Maryland Driving Significant Improvements in Behavioral Health Services Across the State

Retrieved on:

화요일, 12월 5, 2023

Hospitals, Health, Mental Health, Other Health, PHQ-9, MBC, State, Depression, GAD-7, Anxiety, Coordination, Nursing, Greenspace

“There is growing momentum for MBC in Maryland being driven by many clinical and system leaders prioritizing MBC as a foundational component of evidence based service delivery, as they recognize its importance in ensuring high-quality care.

Key Points:

“There is growing momentum for MBC in Maryland being driven by many clinical and system leaders prioritizing MBC as a foundational component of evidence based service delivery, as they recognize its importance in ensuring high-quality care.
This prioritization is clear in the recently announced $120 million in grant funding by the Maryland Consortium on Coordinated Community Support, which strongly encourages the implementation of MBC by providers working in school settings.
It is very promising to see Maryland’s Consortium working to drive improvement and innovation across their behavioral health services.”
To learn more about implementing Measurement-Based Care to enhance the quality of your behavioral health services, please visit greenspacehealth.com .
For more information about Measurment-Based Care and the MDCBH coordinated implementation, please visit:

Aiberry Addresses Growing U.S. Mental Health Needs; Adds Comprehensive Screening Tool Covering Five Major Anxiety Disorders to AI-Powered Assessment Platform

Retrieved on:

화요일, 11월 14, 2023

The comprehensive anxiety screening includes assessments for five distinct anxiety disorders including generalized anxiety disorder, social anxiety disorder, panic disorder, post traumatic stress syndrome (PTSD), and obsessive compulsive disorder (OCD).

Key Points:

The comprehensive anxiety screening includes assessments for five distinct anxiety disorders including generalized anxiety disorder, social anxiety disorder, panic disorder, post traumatic stress syndrome (PTSD), and obsessive compulsive disorder (OCD).
View the full release here: https://www.businesswire.com/news/home/20231114632816/en/
Aiberry's comprehensive anxiety screening includes assessments for five distinct anxiety disorders within Aiberry's innovative AI-powered platform.
(Graphic: Business Wire)
MedPass, a subscription-based platform powered by HealthBird, focused on proactive health management, is partnering with Aiberry on the expanded platform.
Anxiety and mental health are fast becoming a growing issue in the United States with 18% of Americans suffering from anxiety each year , according to the National Institutes of Health.

Ontrak Announces 2023 Third Quarter Financial Results

Retrieved on:

화요일, 11월 14, 2023

Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth-enabled healthcare company, today reported its financial results for the third quarter ended September 30, 2023.

Key Points:

Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth-enabled healthcare company, today reported its financial results for the third quarter ended September 30, 2023.
Revenue for the third quarter of 2023 was $3.7 million, representing a 31% increase compared to the same period in 2022.
Operating loss for the third quarter of 2023 was $(4.1) million compared to an operating loss of $(11.1) million for the same period in 2022.
Adjusted EBITDA for the third quarter of 2023 was $(2.6) million compared to adjusted EBITDA of $(7.7) million for the same period in 2022.

Ellipsis Health and Augmedix to Partner to Bring Automated Mental Health Screenings to Patient Visits

Retrieved on:

목요일, 10월 5, 2023

Triage, Partnership, Health, GAD-7, Anxiety, Human, AI, Mental, Mental health, SDOH, Depression, SAN, API, Attention, Patient, Pharmaceutical industry, Nursing

SAN FRANCISCO, Oct. 5, 2023 /PRNewswire/ -- Ellipsis Health, the market leader in AI-generated vocal biomarker technology for the identification and monitoring of mental health conditions at scale, today announced a plan for a strategic partnership with Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions. The partnership between the parties will mark a significant milestone in healthcare delivery and will allow healthcare providers using Augmedix to incorporate mental health screenings during their clinical encounters, helping to identify issues earlier and triage patients to the appropriate care.

Key Points:

Approximately half the world's population is expected to develop at least one type of mental health disorder by the age of 75.
Augmedix and Ellipsis Health are partnering to address these growing problems, leveraging AI technology to create a more efficient and cost-effective way of automating medical documentation and screening for mental health at scale.
"Augmedix and Ellipsis are well-positioned to collaborate to further address the increasing need for mental health services," shared Ian Shakil, Founder, Director, and Chief Strategy Officer of Augmedix.
For providers, using Augmedix with Ellipsis Health's mental health screening tool is like having a mental health copilot supporting care during every visit."

Magellan Healthcare Releases Clinical White Paper on the Need for Evidence-Based Digital Cognitive Behavioral Therapy Programs

Retrieved on:

화요일, 9월 19, 2023

Magellan Healthcare, Inc. , a leader in behavioral healthcare, has released a clinical white paper outlining the positive, real-world impact of evidence-based digital cognitive behavioral therapy (DCBT).

Key Points:

Magellan Healthcare, Inc. , a leader in behavioral healthcare, has released a clinical white paper outlining the positive, real-world impact of evidence-based digital cognitive behavioral therapy (DCBT).
Americans who suffer from behavioral health concerns need adaptable technologies that:
provide on-demand personalized healthcare journeys, and
offer relevant solutions that engage individuals in their care.
In collaboration with NeuroFlow , Magellan launched the enhanced Digital Emotional Wellbeing suite in January 2022 that included its proven digital cognitive behavioral therapy (DCBT) modules FearFighter®, MoodCalmer, SHADE, RESTORE®, and ComfortAble®.
True evidence-based DCBT follows the exact cognitive behavioral therapy (CBT) process, differing from evidence-informed digital programs that use some CBT practices, but are not built with fidelity to the model.

Ontrak Health's Study of Behavioral Health Patient Reported Outcomes Reveals 53-60% Reduction in Anxiety and Depressive Symptoms

Retrieved on:

목요일, 9월 7, 2023

Technology, Mental Health, Health Technology, Telemedicine, Virtual Medicine, Software, Health, General Health, Data Management, Artificial Intelligence, Anxiety, OTRK, PHQ-9, Depression, GAD-7, Mental health, Grammatical mood, Nursing

Ontrak Health (NASDAQ: OTRK), a leading AI-powered and telehealth-enabled healthcare company, is pleased to announce the results of its 9-month post baseline follow-up behavioral health study that reinforces its positive initial findings.

Key Points:

Ontrak Health (NASDAQ: OTRK), a leading AI-powered and telehealth-enabled healthcare company, is pleased to announce the results of its 9-month post baseline follow-up behavioral health study that reinforces its positive initial findings.
Leveraging industry-recognized PHQ-9 and GAD-7 assessments, Ontrak Health's Wholehealth+ program has contributed to 53-60% reductions in anxiety and depressive symptoms among assessed members.
Key highlights of the study include:
Anxiety Symptoms Improvement: With extended program engagement, 60% of members demonstrated a clinically significant reduction in anxiety symptoms, a marked increase compared to the 30% reported at the six-month mark.
Depressive Symptoms Improvement: An impressive 53% of assessed members experienced a clinically significant reduction in depressive symptoms, consistent with the six-month findings.